SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Preventive Visit — Billie Holiday

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-08-31
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. Holiday is a 33-year-old singer with a severe opioid use disorder on buprenorphine and a moderate alcohol use disorder on acamprosate, who comes for her yearly preventive visit six weeks after her three-month review. Since that visit, when the recovery plan was adjusted after a brief return to use on tour, she has taken buprenorphine every day without a gap and has used no heroin or other opioids. The pharmacy now fills her prescription before each tour, and she carries a travel letter. She drinks one or two drinks on some performance nights and none on most other days. She still carries naloxone and fentanyl test strips. She meets her counselor weekly and her peer recovery coach by phone. Her mood is better, and her PHQ-9 today is 6. She has no new concerns. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 33
Opioid useNone since the return to use before the three-month visit; buprenorphine daily without gaps
AlcoholOne or two drinks on some performance nights; AUDIT-C 3
MoodPHQ-9 6; item 9 scored 0
MedicinesBuprenorphine with naloxone 16 mg daily; acamprosate 666 mg three times daily; thiamine; naloxone spray on hand

Health risk assessment. Completed by the patient on paper in a private room and reviewed with her by Dr. Mayfield; kept in the confidential part of the record with her substance use treatment records. [S]

DomainFinding
Self-rated healthFair, and better than in the spring
PsychosocialSupported by long-time musicians, a close friend, her counselor, and a peer recovery coach; grief for her mother still returns at times
Substance useNo opioid use for six weeks on buprenorphine; AUDIT-C 3
TobaccoAbout five cigarettes a day
Physical activityWalks most days; performing is physically demanding
NutritionIrregular meals on performance days; eating more regularly at home
SleepSix to seven hours, better than at intake
Sexual and reproductive healthSexually active; uses condoms; not planning a pregnancy now
Safety at homeFeels safe at home; no one hurts or threatens her
Road safetyWears a seat belt
Activities of daily livingIndependent
Oral healthNo dental visit in several years

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, night sweats, or weight loss
EyesNegativeNo vision change
Ears, nose, mouth, and throatNegativeNo hoarseness or voice change; no dental pain
CardiovascularNegativeNo chest pain or palpitations
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo abdominal pain, vomiting, black stools, or yellowing of the skin; constipation settled with fiber
GenitourinaryNegativeNo abnormal bleeding or discharge
MusculoskeletalNegativeNo joint pain
IntegumentaryNegativeNo skin infections or abscesses
NeurologicalNegativeNo numbness, tremor, or unsteadiness
PsychiatricNegativeMood better; PHQ-9 score 6; no thoughts of suicide or self-harm; cravings occasional and manageable

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-31Body height165cmS
2026-08-31Body weight68.8kgS
2026-08-31Body mass index (BMI) [Ratio]25.3kg/m2S
2026-08-31Systolic blood pressure118mm[Hg]S
2026-08-31Diastolic blood pressure76mm[Hg]S
2026-08-31Heart rate74/minS
2026-08-31Respiratory rate14/minS
2026-08-31Body temperature36.7CelS
2026-08-31Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-31Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-08-31Total score [AUDIT-C]3{score}S

Physical Exam

Vital signs recorded on 2026-08-31; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 68.8 kg, BMI 25.3; blood pressure 118/76
EyesNo scleral icterus
MouthSeveral teeth with visible decay; no abscess
NeckNo thyroid enlargement or nodes
CardiovascularRegular rhythm; no murmur
RespiratoryClear to auscultation bilaterally
AbdomenSoft and non-tender; liver edge not palpable; no spleen enlargement
SkinNo spider angiomas, palmar erythema, track marks, or abscesses
NeurologicalNo tremor; gait steady
PsychiatricCalm and engaged; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today118/76 mmHg
Cervical cancer screeningOrderedNo result on record; cytology with HPV testing collected today; every five years if normal
Chlamydia and gonorrhea screeningOrderedOffered because of new partners in the past year; urine test today with her agreement
Syphilis screeningOrderedOffered with the other sexual-health tests; drawn today
HIV, hepatitis C, and hepatitis B screeningUp to dateAll nonreactive at intake; repeat yearly while any drug use continues
Pregnancy intention and contraceptionCompleted todayNot planning a pregnancy; uses condoms; other methods discussed and she will think about them. Buprenorphine is safe to continue in pregnancy, and she was told so
Intimate partner violence screeningCompleted todayNegative; she feels safe at home
Depression screeningCompleted todayPHQ-9 score 6, down from 11 six weeks ago; item 9 scored 0
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 3, from 8 at intake; in treatment
Tobacco cessationDeclinedAbout five cigarettes a day; nicotine replacement and counseling offered; she is not ready and will say when she is
Diabetes and cholesterol screeningNot indicatedDiabetes screening begins at 35 for adults who are overweight; statin assessment begins at 40
Breast and colorectal cancer screeningNot indicatedBegin at 40 and 45
Hepatitis A vaccineDueDose 2 at the six-month visit
Hepatitis B vaccineUp to dateTwo-dose series complete
Pneumococcal vaccineUp to datePCV20 at intake, recommended for adults with alcohol use disorder
Tetanus, diphtheria, and pertussisUp to dateTdap at intake
Influenza and COVID-19 vaccines, this seasonDueInfluenza vaccine at the six-month visit; COVID-19 vaccine discussed and she will decide then
HPV vaccineDeclinedShared decision-making for adults 27 to 45; she chose not to have it
Dental examinationReferredVisible decay and no dental visit in several years; dry mouth from buprenorphine discussed; dental appointment arranged

Guideline basis: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026)

Follow-up: Six-month recovery review in seven weeks, with PEth, liver tests, blood count, the second hepatitis A dose, and the influenza vaccine. Sexual-health and cervical screening results by phone, as she asked. Dental appointment arranged. Next preventive visit in one year. Next scheduled visit 2026-10-19: six-month recovery, alcohol, liver, and mood review. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 16 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the confidential part of the chart and is not named here. She said that what matters most to her is her music, being treated with respect, and deciding for herself who learns about her health. She chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. [S]